Author: Chang Chen; Jianying Huang; Zhenshun Cheng; Jianyuan Wu; Song Chen; Yongxi Zhang; Bo Chen; Mengxin Lu; Yongwen Luo; Jingyi Zhang; Ping Yin; Xinghuan Wang
Title: Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial Document date: 2020_3_20
ID: 14he8n3u_16
Snippet: Secondary outcomes included the latency to pyrexia relief (for patients with pyrexia at the time of enrollment), the latency to cough relief (for patients with moderate or severe cough at the time of enrollment), the rate of AOT or NMV, all-cause mortality, dyspnea, rate of respiratory failure (defined as SPO 2 ≤ 90% without oxygen inhalation or PaO 2 /FiO 2 <300mmHg, requires oxygen therapy or additional respiratory support), and the rate of p.....
Document: Secondary outcomes included the latency to pyrexia relief (for patients with pyrexia at the time of enrollment), the latency to cough relief (for patients with moderate or severe cough at the time of enrollment), the rate of AOT or NMV, all-cause mortality, dyspnea, rate of respiratory failure (defined as SPO 2 ≤ 90% without oxygen inhalation or PaO 2 /FiO 2 <300mmHg, requires oxygen therapy or additional respiratory support), and the rate of patients needed to receive intensive care in ICU. Safety outcomes All rights reserved. No reuse allowed without permission.
Search related documents:
Co phrase search for related documents- additional respiratory support and intensive care: 1, 2
- additional respiratory support and oxygen therapy: 1
- additional respiratory support and respiratory support: 1, 2, 3, 4, 5
- cause mortality and enrollment time: 1
- cause mortality and intensive care: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- cause mortality and intensive care receive: 1
- cause mortality and NMV AOT rate: 1
- cause mortality and oxygen inhalation: 1
- cause mortality and oxygen therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- cause mortality and patient rate: 1, 2, 3, 4, 5, 6, 7, 8
- cause mortality and pyrexia patient: 1
- cause mortality and pyrexia relief: 1
- cause mortality and pyrexia relief latency: 1
- cause mortality and relief cough: 1
- cause mortality and relief cough latency: 1
- cause mortality and respiratory failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- cause mortality and respiratory failure rate: 1, 2, 3, 4
- cause mortality and respiratory failure rate dyspnea: 1
- cause mortality and respiratory failure rate dyspnea cause mortality: 1
Co phrase search for related documents, hyperlinks ordered by date